A citation-based method for searching scientific literature

Mark L Wahlqvist, Meei-Shyuan Lee, Chih-Cheng Hsu, Shao-Yuan Chuang, Jiunn-Tay Lee, Hsin-Ni Tsai. Parkinsonism Relat Disord 2012
Times Cited: 149







List of co-cited articles
1445 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


Neuroprotective effect of metformin in MPTP-induced Parkinson's disease in mice.
S P Patil, P D Jain, P J Ghumatkar, R Tambe, S Sathaye. Neuroscience 2014
160
33

Type 2 diabetes and the risk of Parkinson's disease.
Gang Hu, Pekka Jousilahti, Siamak Bidel, Riitta Antikainen, Jaakko Tuomilehto. Diabetes Care 2007
291
29

Metformin lowers α-synuclein phosphorylation and upregulates neurotrophic factor in the MPTP mouse model of Parkinson's disease.
Nikita Katila, Sunil Bhurtel, Sina Shadfar, Sunil Srivastav, Sabita Neupane, Uttam Ojha, Gil-Saeng Jeong, Dong-Young Choi. Neuropharmacology 2017
85
31


Effects of metformin exposure on neurodegenerative diseases in elderly patients with type 2 diabetes mellitus.
Yi-Chun Kuan, Kuang-Wei Huang, Cheng-Li Lin, Chaur-Jong Hu, Chia-Hung Kao. Prog Neuropsychopharmacol Biol Psychiatry 2017
80
32

Glitazone use associated with reduced risk of Parkinson's disease.
Brage Brakedal, Irene Flønes, Simone F Reiter, Øivind Torkildsen, Christian Dölle, Jörg Assmus, Kristoffer Haugarvoll, Charalampos Tzoulis. Mov Disord 2017
64
39

Exenatide once weekly versus placebo in Parkinson's disease: a randomised, double-blind, placebo-controlled trial.
Dilan Athauda, Kate Maclagan, Simon S Skene, Martha Bajwa-Joseph, Dawn Letchford, Kashfia Chowdhury, Steve Hibbert, Natalia Budnik, Luca Zampedri, John Dickson,[...]. Lancet 2017
354
24

Metformin, other antidiabetic drugs, and risk of Alzheimer's disease: a population-based case-control study.
Patrick Imfeld, Michael Bodmer, Susan S Jick, Christoph R Meier. J Am Geriatr Soc 2012
234
23

Diabetes and the risk of developing Parkinson's disease in Denmark.
Eva Schernhammer, Johnni Hansen, Kathrine Rugbjerg, Lene Wermuth, Beate Ritz. Diabetes Care 2011
120
22

Diabetes and risk of Parkinson's disease.
Qun Xu, Yikyung Park, Xuemei Huang, Albert Hollenbeck, Aaron Blair, Arthur Schatzkin, Honglei Chen. Diabetes Care 2011
167
22

The Therapeutic Potential of Metformin in Neurodegenerative Diseases.
Carola Rotermund, Gerrit Machetanz, Julia C Fitzgerald. Front Endocrinol (Lausanne) 2018
138
22

Exenatide and the treatment of patients with Parkinson's disease.
Iciar Aviles-Olmos, John Dickson, Zinovia Kefalopoulou, Atbin Djamshidian, Peter Ell, Therese Soderlund, Peter Whitton, Richard Wyse, Tom Isaacs, Andrew Lees,[...]. J Clin Invest 2013
286
21

Diabetes and risk of Parkinson's disease: a systematic review and meta-analysis.
Emanuele Cereda, Michela Barichella, Carlo Pedrolli, Catherine Klersy, Erica Cassani, Riccardo Caccialanza, Gianni Pezzoli. Diabetes Care 2011
138
20

Metformin lowers Ser-129 phosphorylated α-synuclein levels via mTOR-dependent protein phosphatase 2A activation.
B I Pérez-Revuelta, M M Hettich, A Ciociaro, C Rotermund, P J Kahle, S Krauss, D A Di Monte. Cell Death Dis 2014
86
23

Risk of Parkinson Disease in Diabetes Mellitus: An Updated Meta-Analysis of Population-Based Cohort Studies.
Xuejing Yue, Hehua Li, Haiqing Yan, Ping Zhang, Li Chang, Tong Li. Medicine (Baltimore) 2016
80
25

Risk of Parkinson disease onset in patients with diabetes: a 9-year population-based cohort study with age and sex stratifications.
Yu Sun, Ya-Hui Chang, Hua-Fen Chen, Ying-Hwa Su, Hui-Fang Su, Chung-Yi Li. Diabetes Care 2012
125
19

Increased risk of cognitive impairment in patients with diabetes is associated with metformin.
Eileen M Moore, Alastair G Mander, David Ames, Mark A Kotowicz, Ross P Carne, Henry Brodaty, Michael Woodward, Karyn Boundy, Kathryn A Ellis, Ashley I Bush,[...]. Diabetes Care 2013
223
19

Incidence of dementia is increased in type 2 diabetes and reduced by the use of sulfonylureas and metformin.
Chih-Cheng Hsu, Mark L Wahlqvist, Meei-Shyuan Lee, Hsin-Ni Tsai. J Alzheimers Dis 2011
240
19


Parkinson's disease, insulin resistance and novel agents of neuroprotection.
Iciar Aviles-Olmos, Patricia Limousin, Andrew Lees, Thomas Foltynie. Brain 2013
189
18

Motor and cognitive advantages persist 12 months after exenatide exposure in Parkinson's disease.
Iciar Aviles-Olmos, John Dickson, Zinovia Kefalopoulou, Atbin Djamshidian, Joshua Kahan, Peter Ell, Peter Whitton, Richard Wyse, Tom Isaacs, Andrew Lees,[...]. J Parkinsons Dis 2014
166
18

Metformin, besides exhibiting strong in vivo anti-inflammatory properties, increases mptp-induced damage to the nigrostriatal dopaminergic system.
Afrah A K Ismaiel, Ana M Espinosa-Oliva, Martiniano Santiago, Albert García-Quintanilla, María J Oliva-Martín, Antonio J Herrera, José L Venero, Rocío M de Pablos. Toxicol Appl Pharmacol 2016
41
41

Glitazone Treatment and Incidence of Parkinson's Disease among People with Diabetes: A Retrospective Cohort Study.
Ruth Brauer, Krishnan Bhaskaran, Nishi Chaturvedi, David T Dexter, Liam Smeeth, Ian Douglas. PLoS Med 2015
82
19

Loss of insulin receptor immunoreactivity from the substantia nigra pars compacta neurons in Parkinson's disease.
I Moroo, T Yamada, H Makino, I Tooyama, P L McGeer, E G McGeer, K Hirayama. Acta Neuropathol 1994
118
16

Quantification of metformin by the HPLC method in brain regions, cerebrospinal fluid and plasma of rats treated with lipopolysaccharide.
Krzysztof Łabuzek, Dariusz Suchy, Bożena Gabryel, Anna Bielecka, Sebastian Liber, Bogusław Okopień. Pharmacol Rep 2010
237
16

Role of AMP-activated protein kinase in mechanism of metformin action.
G Zhou, R Myers, Y Li, Y Chen, X Shen, J Fenyk-Melody, M Wu, J Ventre, T Doebber, N Fujii,[...]. J Clin Invest 2001
15

Effects of the Insulin Sensitizer Metformin in Alzheimer Disease: Pilot Data From a Randomized Placebo-controlled Crossover Study.
Aaron M Koenig, Dawn Mechanic-Hamilton, Sharon X Xie, Martha F Combs, Anne R Cappola, Long Xie, John A Detre, David A Wolk, Steven E Arnold. Alzheimer Dis Assoc Disord 2017
157
15

Metformin Prevents Nigrostriatal Dopamine Degeneration Independent of AMPK Activation in Dopamine Neurons.
Jacqueline A Bayliss, Moyra B Lemus, Vanessa V Santos, Minh Deo, Jeffrey S Davies, Bruce E Kemp, John D Elsworth, Zane B Andrews. PLoS One 2016
40
37

Long-term metformin usage and cognitive function among older adults with diabetes.
Tze Pin Ng, Liang Feng, Keng Bee Yap, Tih Shih Lee, Chay Hoon Tan, Bengt Winblad. J Alzheimers Dis 2014
195
15

Diabetes mellitus and Parkinson disease.
Gennaro Pagano, Sotirios Polychronis, Heather Wilson, Beniamino Giordano, Nicola Ferrara, Flavia Niccolini, Marios Politis. Neurology 2018
95
15


Insulin resistance impairs nigrostriatal dopamine function.
J K Morris, G L Bomhoff, B K Gorres, V A Davis, J Kim, P-P Lee, W M Brooks, G A Gerhardt, P C Geiger, J A Stanford. Exp Neurol 2011
93
15

GLP-1 receptor stimulation preserves primary cortical and dopaminergic neurons in cellular and rodent models of stroke and Parkinsonism.
Yazhou Li, TracyAnn Perry, Mark S Kindy, Brandon K Harvey, David Tweedie, Harold W Holloway, Kathleen Powers, Hui Shen, Josephine M Egan, Kumar Sambamurti,[...]. Proc Natl Acad Sci U S A 2009
407
14

Glucagon-like peptide 1 receptor stimulation reverses key deficits in distinct rodent models of Parkinson's disease.
Alexander Harkavyi, Amjad Abuirmeileh, Rebecca Lever, Ann E Kingsbury, Christopher S Biggs, Peter S Whitton. J Neuroinflammation 2008
194
14

Peptide hormone exendin-4 stimulates subventricular zone neurogenesis in the adult rodent brain and induces recovery in an animal model of Parkinson's disease.
Göran Bertilsson, Cesare Patrone, Olof Zachrisson, Annica Andersson, Karin Dannaeus, Jessica Heidrich, Jarkko Kortesmaa, Alex Mercer, Elisabet Nielsen, Harriet Rönnholm,[...]. J Neurosci Res 2008
244
14

Demonstrated brain insulin resistance in Alzheimer's disease patients is associated with IGF-1 resistance, IRS-1 dysregulation, and cognitive decline.
Konrad Talbot, Hoau-Yan Wang, Hala Kazi, Li-Ying Han, Kalindi P Bakshi, Andres Stucky, Robert L Fuino, Krista R Kawaguchi, Andrew J Samoyedny, Robert S Wilson,[...]. J Clin Invest 2012
14

Metformin reverses TRAP1 mutation-associated alterations in mitochondrial function in Parkinson's disease.
Julia C Fitzgerald, Alexander Zimprich, Daniel A Carvajal Berrio, Kevin M Schindler, Brigitte Maurer, Claudia Schulte, Christine Bus, Anne-Kathrin Hauser, Manuela Kübler, Rahel Lewin,[...]. Brain 2017
62
22

Association between diabetes and subsequent Parkinson disease: A record-linkage cohort study.
Eduardo De Pablo-Fernandez, Raph Goldacre, Julia Pakpoor, Alastair J Noyce, Thomas T Warner. Neurology 2018
112
14


Clinical features of Parkinson disease when onset of diabetes came first: A case-control study.
E Cereda, M Barichella, E Cassani, R Caccialanza, G Pezzoli. Neurology 2012
92
14

Antidiabetic drug metformin (GlucophageR) increases biogenesis of Alzheimer's amyloid peptides via up-regulating BACE1 transcription.
Yaomin Chen, Kun Zhou, Ruishan Wang, Yun Liu, Young-Don Kwak, Tao Ma, Robert C Thompson, Yongbo Zhao, Layton Smith, Laura Gasparini,[...]. Proc Natl Acad Sci U S A 2009
296
13

AMP kinase activation mitigates dopaminergic dysfunction and mitochondrial abnormalities in Drosophila models of Parkinson's disease.
Chee-Hoe Ng, Melissa S H Guan, Cherlyn Koh, Xuezhi Ouyang, Fengwei Yu, Eng-King Tan, Sharon Philomena O'Neill, Xiaodong Zhang, Jongkyeong Chung, Kah-Leong Lim. J Neurosci 2012
111
13

Metformin improves healthspan and lifespan in mice.
Alejandro Martin-Montalvo, Evi M Mercken, Sarah J Mitchell, Hector H Palacios, Patricia L Mote, Morten Scheibye-Knudsen, Ana P Gomes, Theresa M Ward, Robin K Minor, Marie-José Blouin,[...]. Nat Commun 2013
777
13


Biguanide metformin acts on tau phosphorylation via mTOR/protein phosphatase 2A (PP2A) signaling.
Eva Kickstein, Sybille Krauss, Paul Thornhill, Désirée Rutschow, Raphael Zeller, John Sharkey, Ritchie Williamson, Melanie Fuchs, Andrea Köhler, Hartmut Glossmann,[...]. Proc Natl Acad Sci U S A 2010
294
13

Shared dysregulated pathways lead to Parkinson's disease and diabetes.
Jose A Santiago, Judith A Potashkin. Trends Mol Med 2013
139
12

Reduced incidence of Parkinson's disease after dipeptidyl peptidase-4 inhibitors-A nationwide case-control study.
Per Svenningsson, Karin Wirdefeldt, Li Yin, Fang Fang, Ioanna Markaki, Suad Efendic, Jonas F Ludvigsson. Mov Disord 2016
42
28

Increased risk of Parkinson disease with diabetes mellitus in a population-based study.
Yu-Wan Yang, Teng-Fu Hsieh, Chia-Ing Li, Chiu-Shong Liu, Wen-Yuan Lin, Jen-Huai Chiang, Tsai-Chung Li, Cheng-Chieh Lin. Medicine (Baltimore) 2017
62
19

Activation of the ATF2/CREB-PGC-1α pathway by metformin leads to dopaminergic neuroprotection.
Hojin Kang, Rin Khang, Sangwoo Ham, Ga Ram Jeong, Hyojung Kim, Minkyung Jo, Byoung Dae Lee, Yun Il Lee, Areum Jo, ChiHu Park,[...]. Oncotarget 2017
37
32

Effect of metformin on neurodegenerative disease among elderly adult US veterans with type 2 diabetes mellitus.
Qian Shi, Shuqian Liu, Vivian A Fonseca, Tina K Thethi, Lizheng Shi. BMJ Open 2019
45
26


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.